Skip to content
    BRKR
    Earnings call· Jun 2026(Q2 FY26)

    BRUKER Q2 FY26 earnings call BRKR

    Aug 4, 2026 Source

    Executive summary

    Bruker Q2 FY26 — Return to Organic Growth and Strong Deep Tech Orders

    Bruker returned to organic revenue growth in Q2 FY26, driven by strong demand in deep tech and biopharma, despite continued weakness in U.S. academic markets and China revenue declines. The company delivered significant margin expansion and EPS growth, benefiting from cost reduction initiatives and tariff refunds. Management expects continued profitability improvements and double-digit EPS growth in FY26 and FY27, supported by a strong order book and a new operating structure.

    Highlights

    5

    • Returned to organic revenue growth of 2.8% in Q2 FY26, or 3.4% excluding tariff refunds.

    • Scientific Instruments segment achieved 10% organic bookings growth year-over-year, with book-to-bill above 1.0 for the fourth consecutive quarter.

    • Deep tech semiconductor tools and energy research technologies saw over 50% organic order growth year-over-year in Q2.

    • Non-GAAP diluted EPS increased 53% to $0.49 in Q2 FY26, driven by cost reductions and tariff refunds.

    • Achieved $30 million in cost savings in Q2, on track for $140 million annualized savings in FY26.

    Concerns

    5

    • U.S. academic orders remained weak in Q2, with U.S. ACA/GOV revenues down more than $15 million year-over-year.

    • Asia Pacific revenue declined in the low double digits percentage in Q2, including a low double-digit decline in China.

    • Q2 FY26 reported revenues were at the low end of expectations, unfavorably impacted by tariff refunds (on revenue growth) and a stronger U.S. dollar.

    • Non-GAAP effective tax rate increased to 25% from 23.6% in Q2 FY25.

    • GAAP results include a noncash goodwill impairment charge of $135 million related to automation and spatial biology businesses.

    Guidance & targets

    13
    CategoryTargetConfidence
    Full-year 2026 Reported Revenue
    $3.54 billion to $3.57 billion
    high materiality
    High
    Full-year 2026 Organic Revenue Growth
    1% to 2% year-over-year
    high materiality
    High
    Full-year 2026 Acquisitions Contribution to Growth
    1.5%
    medium materiality
    High
    Full-year 2026 Non-GAAP Operating Margin Expansion
    250 to 300 basis points year-over-year
    high materiality
    High
    Full-year 2026 Non-GAAP EPS
    $2.10 to $2.15
    high materiality
    High
    Q3 FY26 Organic Revenue
    roughly flat to up slightly year-over-year
    medium materiality
    Medium
    Q3 FY26 Operating Margins and EPS
    slight sequential decrease
    medium materiality
    Medium
    Q4 FY26 Organic Revenue Growth, Operating Margin, and EPS
    meaningful sequential and year-over-year increases
    high materiality
    High
    FY27 Additional Cost Reductions
    $20 million
    medium materiality
    High
    FY27 Margin Growth
    well above 100 bps
    medium materiality
    Medium
    FY27 Non-GAAP EPS Growth
    double-digit, hopefully, mid-teens
    high materiality
    Medium
    Long-term Operating Margin Target
    drive back towards a 20% EBIT operating margin as quickly as possible and then more gradually move up to the low 20s in EBIT and mid-20s in EBITDA
    high materiality
    High
    Q4 FY26 Revenue Expectation
    around the $1 billion range
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    BioSpin Group
    H1 FY26 revenue. Saw strong revenue growth in hospital clinical and biopharma, offset by weakness in China, ACA/GOV, food testing, and automation. NMR preclinical and preclinical imaging had robust order growth (double digits in H1).
    		$393 milliondown mid-single digits percentage——
    CALID Group
    H1 FY26 revenue. Driven by mass spectrometry, including the Tofwork acquisition. Saw strength in biopharma, security detection, and European ACA/GOV, partially offset by weaker revenues in the U.S. Molecular Diagnostics solid H1 revenue growth, microbiology roughly flat.
    		$627 millionincreased in the mid-single-digit percentage——
    Bruker Nano
    H1 FY26 revenue. Saw weakness in ACA/GOV industrial markets, while weakness in U.S. ACA/GOV funding continued to impact spatial biology. This was largely offset by robust strength in semiconductor metrology due to AI-driven orders.
    		$507 millionlow single-digit percentage decline——
    BEST (Bruker Energy and Supercon Technologies)
    H1 FY26 revenue growth, net of intercompany eliminations. Strong growth in the superconductor business and solid revenue growth at Research Instruments (RRI). RRI secured very strong multiyear orders for Fusion Energy and high-energy physics technologies in H1.
    		—up 6%——

    Operational metrics

    42
    Reported Revenue
    $838.5 millionup 5.2% YoY
    Q2 FY26

    Reflecting a pivot to organic growth.

    Organic Revenue Growth
    2.8%YoY
    Q2 FY26

    3.4% organic growth excluding tariff refunds.

    M&A Contribution to Revenue
    1.5%
    Q2 FY26

    Contribution to top line.

    FX Impact on Revenue
    0.9%tailwind
    Q2 FY26

    50 bps lower than originally expected.

    Constant Exchange Rate Revenue Growth
    4.3%YoY
    Q2 FY26

    Constant exchange rate revenue growth.

    Non-GAAP Gross Margin
    52.1%increased 350 bps YoY
    Q2 FY26

    Up significantly year-over-year, including net U.S. tariff refund benefit.

    Non-GAAP Operating Margin
    14.1%up 510 bps YoY
    Q2 FY26

    Driven by cost saving actions, positive net U.S. tariff impact, and favorable volume mix.

    Non-GAAP Operating Margin Impact from Tariff Refunds
    200
    Q2 FY26

    Added around 200 basis points to Q2 operating margins.

    Non-GAAP Diluted EPS
    $0.49up 53% from $0.32 in Q2 FY25
    Q2 FY26

    Diluted non-GAAP EPS.

    Non-GAAP EPS Impact from Tariff Refunds
    $0.06
    Q2 FY26

    Net U.S. tariffs contributed about $0.06 to EPS.

    Non-GAAP Effective Tax Rate
    25%compared to 23.6% in Q2 FY25
    Q2 FY26

    Non-GAAP effective tax rate.

    GAAP Diluted EPS
    loss of $0.41compared to $0.05 in Q2 FY25
    Q2 FY26

    GAAP diluted loss per share, includes goodwill impairment.

    Goodwill Impairment Charge
    $135 million
    Q2 FY26

    Noncash charge related to automation and spatial biology businesses.

    Weighted Average Diluted Shares Outstanding
    152.8 millionincrease of 1.1 million shares from Q2 FY25
    Q2 FY26

    Weighted average diluted shares outstanding.

    Net Leverage Ratio
    2.8x
    as of June 30, 2026

    As of June 30, 2026, on stronger EBITDA.

    Reported Revenue
    EUR 1.66 billionincreased 3.9%
    H1 FY26

    H1 FY26 revenues.

    Organic Revenue Growth
    decline of 0.8%
    H1 FY26

    First half organic revenue.

    Semiconductor Metrology Organic Order Growth
    greater than 30%
    H1 FY26

    For semiconductor metrology nano tools.

    Semiconductor Metrology Organic Revenue Growth
    greater than 15%
    H1 FY26

    For semiconductor metrology nano tools, somewhat lagging order growth.

    Semiconductor Metrology EBIT Margin
    about 30%
    H1 FY26

    This business is very profitable.

    Security Detection Orders Growth
    approximately 20%YoY
    H1 FY26

    For security detection business.

    Security Detection Revenue Growth
    approximately 20%YoY
    H1 FY26

    For security detection business.

    Research Instruments Orders Growth
    well over 100%YoY
    H1 FY26

    For energy research business (RRI).

    Cost Savings Realized
    $30 million
    Q2 FY26

    Delivered in the second quarter.

    Annualized Cost Savings Goal
    $140 million
    FY26

    Stated goal for 2026.

    FY27 Additional Cost Reductions
    $20 million
    FY27

    Expected from the new operating structure.

    Deep Tech Portfolio as % of Total
    around 15%
    Current

    Includes semiconductor metrology, security detection, energy research, excluding Supercon Technologies.

    Americas Organic Revenue Growth
    approximately 10%YoY
    Q2 FY26

    Geographic organic revenue growth.

    European Organic Revenue Growth
    approximately 10%YoY
    Q2 FY26

    Geographic organic revenue growth.

    Asia Pacific Revenue Decline
    low double digits percentage
    Q2 FY26

    Geographic revenue decline.

    China Revenue Decline
    low double digits
    Q2 FY26

    Included in Asia Pacific decline.

    EMEA Revenue Decline
    low single-digit percentage
    Q2 FY26

    Geographic revenue decline.

    BSI Segment Order Book Organic Growth
    10%YoY
    Q2 FY26

    Solid organic growth, driven by semi and biopharma.

    BSI Segment Order Book Growth (Semi)
    greater than 50%
    Q2 FY26

    Within BSI segment order book.

    BSI Segment Order Book Growth (Biopharma)
    greater than 20%
    Q2 FY26

    Within BSI segment order book.

    U.S. ACA/GOV Revenue Decline
    more than $15 millionYoY
    Q2 FY26

    Result of weak orders in H2 FY25.

    Europe ACA/GOV Orders Growth
    more than 10%
    Q2 FY26

    For academic and medical research business.

    China ACA/GOV Orders Growth
    more than 20%
    Q2 FY26

    For academic and medical research business.

    Q3 FY26 Revenue Shift to Q4
    $20 million
    Q3 FY26

    Previously planned Q3 revenue shifting to Q4 due to semiconductor customer delivery requirements.

    Q4 FY26 Revenue (Implied)
    $1.02 billion
    Q4 FY26

    Implied Q4 revenue based on management's commentary. The analyst's quote included an ASR error of '$1.4 million' which is not captured as a valid figure. Management confirmed 'around the $1 billion range'. The $1.02 billion is the lower bound of the analyst's calculation validated by management's general agreement.

    U.S. ACA/GOV Orders Growth
    —
    Q2 FY26

    U.S. academic orders remained weak in Q2, not yet translating NIH outlays into significant orders.

    Deep Tech Revenue Contribution
    —
    Q4 FY26 and beyond

    Strong deep tech bookings will benefit Q4 FY26 and significantly contribute to revenue and P&L in FY27 and outer years due to long lead times.

    Industry KPIs

    9
    MetricValueDetails
    Revenue EPS guidanceFY26 organic revenue growth 1% to 2% YoY; non-GAAP EPS $2.10 to $2.15%
    China revenue exposurelow double digits%
    Pricing price realizationsome pricing benefit
    Diagnostics testing demandsolid
    M a contribution synergies1.5%%
    Segment organic revenue growth2.3%%
    Bioprocessing orders book to billabove 1.0
    Instruments vs consumables services mixmid-single digits%
    Organic core revenue growth by end market10%%

    Risks & headwinds

    5
    U.S. Academic Funding WeaknessQ2 FY26, ongoing impact from H2 FY25 orders.

    U.S. ACA/GOV revenues down more than $15 million YoY in Q2 FY26.

    Mitigation: Expectation of eventual NIH outlays translating into orders, with potential Q3 budget flush leading to Q4 bookings.

    Asia Pacific / China Revenue DeclineQ2 FY26.

    Asia Pacific revenue declined low double digits percentage in Q2 FY26, including a low double-digit decline in China.

    Mitigation: China ACA/GOV orders were up >20% in Q2, suggesting potential future revenue recovery with a typical 6-month delay.

    Goodwill Impairment ChargeQ2 FY26.

    Noncash goodwill impairment charges of $135 million.

    Mitigation: Related to automation and spatial biology businesses which continued to experience operating losses; implies ongoing challenges in these specific business areas.

    FX HeadwindFY26, particularly Q3 and Q4.

    Foreign exchange tailwind to revenues reduced from 1.5% to 0.5% for FY26, turning into a revenue headwind in Q3 and Q4, with about $15 million impact in Q3.

    Mitigation: Guidance updated to reflect FX rates as of June 30, 2026.

    Supply Chain ChallengesCurrent.

    Not quantified.

    Mitigation: Some challenges around componentry (electronics side), but management is comfortable it's baked into current guidance.

    What to watch in Q3 FY26

    5

    U.S. Academic & Government (ACA/GOV) Orders

    Q3 FY26 and beyond
    Currentstill weak in Q2, revenues down >$15 million YoY
    TargetImprovement in order intake, especially from NIH outlays and Q3 budget flush.

    Why it matters

    U.S. ACA/GOV is a significant market; recovery in orders would boost overall growth and indicate broader market health.

    U.S. academic orders still remained weak in Q2... We will observe what's happening in Q3 and, of course, the Q3 budget flush, which seems to be underway, could, for us, also mean decent Q4 U.S. ACA/GOV bookings.

    Q&A highlights

    6

    Clarify how tariff refunds are treated (pass-through vs. profit) and their embedding in H2/FY guidance.

    Gerald Herman explained that some tariff elements were contra-revenue, but refunds added ~200 bps to Q2 operating margins and $0.06 to EPS. The H2 impact was already factored into original guidance, just pulled forward to Q2.

    “with respect to EPS, we've also indicated that, that generated roughly 200 basis points of margin expansion in the quarter for the second quarter. As far as the second half goes, we've already factored that or baked that into our earlier guide numbers.”

    asked by Puneet Souda · answered by Gerald Herman

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Reorganization for Integrated Workflows

    Bruker implemented a new operating structure effective July 1, 2026, combining its BioSpin, Daltonics, and Optics divisions into a new Bruker Biosystems group. This reorganization aims to address the growing need for scientific integration in the post-genomic era, connecting complementary life science research workflows for comprehensive disease biology insights. The new structure is expected to drive an additional $20 million in cost reductions in fiscal year 2027, enhancing group-level agility and investment prioritization for innovation.

    02

    Strong Deep Tech Order Growth

    The company experienced robust order growth in its deep tech areas, with semiconductor metrology and energy research technologies seeing over 50% organic order growth in Q2 FY26. These proprietary capabilities, including security detection systems, are valuable as life science research demand recovers. These orders, often with 9-24 month lead times, are expected to benefit Q4 FY26 and significantly contribute to revenue and P&L in FY27 and beyond, indicating strong sustainability and visibility for the next 6+ quarters.

    03

    Cost Reduction and Margin Expansion

    Bruker made significant progress on cost actions, realizing $30 million in Q2 FY26 and remaining on track for $140 million in annualized cost savings for FY26. This focus on cost reductions, combined with favorable mix and volume, drove a 350 basis point increase in non-GAAP gross margin to 52.1% and a 510 basis point increase in non-GAAP operating margin to 14.1% in Q2. The company aims for continued margin expansion and double-digit EPS growth in FY26 and FY27, targeting a 20% EBIT operating margin long-term.

    04

    Geographic and End-Market Dynamics

    While Americas and European revenues grew approximately 10% organically in Q2 FY26, Asia Pacific revenue declined in the low double digits, including China. U.S. academic orders remained weak, impacting spatial biology, but were offset by strength in biopharma, security detection, and European academic markets. China orders for ACA/GOV were up over 20% in Q2, suggesting a potential revenue recovery in future quarters, reflecting a typical 6-month delay between orders and revenue.

    05

    Q4 FY26 Revenue and Margin Setup

    Management anticipates a strong Q4 FY26 with meaningful sequential and year-over-year increases in organic revenue growth, operating margin, and EPS. This is attributed to a shift of approximately $20 million in semiconductor customer delivery requirements from Q3 to Q4, the expected delivery of ultra-high field systems, and a favorable mix and higher volume. The company expects Q4 revenue to be around $1 billion, supported by a strong backlog and seasonal trends.

    AI-generated summary of the company’s earnings call. Not investment advice.